Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q9NQ40: Variant p.Val413Ala

Solute carrier family 52, riboflavin transporter, member 3
Gene: SLC52A3
Feedback?
Variant information Variant position: help 413 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Valine (V) to Alanine (A) at position 413 (V413A, p.Val413Ala). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (V) to small size and hydrophobic (A) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In BVVLS1. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 413 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 469 The length of the canonical sequence.
Location on the sequence: help WGGEVLIVASWVLFSGCLSY V KVMLGVVLRDLSRSALLWCG The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         WGGEVLIVASWVLFSGCLSYVKVMLGVVLRDLSRSALLWCG

Mouse                         WGGEVLIVLSWVLFAACLSYVKVMLGVILRDRSRSALLWCG

Rat                           WGGEVLIVLSWMLFVACLSYVKVMLGVILRDRSRSALLWCG

Bovine                        WGGEVLIVVSWVLFTGCLSYVKVMLGVILRDHSRSALLWCG
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 469 Solute carrier family 52, riboflavin transporter, member 3
Transmembrane 397 – 417 Helical
Disulfide bond 386 – 463
Alternative sequence 401 – 415 ASWVLFSGCLSYVKV -> SIRPVGLLPLRTPHP. In isoform 2.



Literature citations
Brown-Vialetto-Van Laere syndrome, a ponto-bulbar palsy with deafness, is caused by mutations in c20orf54.
Green P.; Wiseman M.; Crow Y.J.; Houlden H.; Riphagen S.; Lin J.P.; Raymond F.L.; Childs A.M.; Sheridan E.; Edwards S.; Josifova D.J.;
Am. J. Hum. Genet. 86:485-489(2010)
Cited for: VARIANTS BVVLS1 LYS-36; TRP-132; LEU-224; ALA-413 AND LEU-457; VARIANT MET-350; Brown-Vialetto-van Laere and Fazio-Londe overlap syndromes: a clinical, biochemical and genetic study.
Ciccolella M.; Catteruccia M.; Benedetti S.; Moroni I.; Uziel G.; Pantaleoni C.; Chiapparini L.; Bizzi A.; D'Amico A.; Fattori F.; Salsano M.L.; Pastore A.; Tozzi G.; Piemonte F.; Bertini E.;
Neuromuscul. Disord. 22:1075-1082(2012)
Cited for: VARIANTS BVVLS1 ASP-58; TRP-266; SER-319 AND ALA-413; VARIANT VAL-303;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.